Pfizer Starts Pivotal Phase 3 Study of mRNA-Based Influenza Vaccine
Pfizer Inc (NYSE:PFE) has dosed the first participants in the Phase 3 trial of its quadrivalent modified RNA (modRNA) influenza vaccine…
Aytu BioPharma Announces Addition Of Fourth Patent License For AR101/Enzastaurin
ENGLEWOOD, CO / ACCESSWIRE / September 14, 2022 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, with a
After Investor Flak, German Healthcare Giant Bayer Starts Hunt For New CEO: Report
Bayer AG (OTC:BAYRY) has started a hunt for CEO Werner Baumann’s successor, Bloomberg News reported, citing people close to the…
BioCardia Announces CardiAMP Cell Therapy Heart Failure Trial Two Year Roll-In Cohort Data To Be Presented At Heart Failure Society Of America Annual Meeting
Sunnyvale, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today
NGM Bio Presents Preliminary Data From NGM120 Combo Trial In Pancreatic Cancer
NGM Biopharmaceuticals Inc (NASDAQ:NGM) announced updated preliminary findings from its Phase 1b dose escalation trial of NGM120 in metastatic pancreatic cancer.…
Important Biotech Catalysts For September 13, 2022 – End Of The Day Summary
Akero Therapeutics (NASDAQ:AKRO) revealed topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety…
NGM Bio Presents Updated Preliminary Findings From Ongoing Phase 1b Dose Escalation Trial Of NGM120 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Cancer At AACR Special Conference: Pancreatic Cancer
NGM120 is a novel antagonist antibody that binds GFRAL and inhibits GDF15 signaling for the potential treatment of cancer
NGM120 has been well tolerated to date in patients in the Phase 1b combination cohort (NGM120 +
GENFIT Gets FDA Orphan Drug Status For Liver Disease Candidate
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to GENFIT’s (NASDAQ: GNFT) drug candidate GNS5611 (ezurpimtrostat) for the treatment of cholangiocarcinoma.
Conformis Shares Shoot Higher Following FDA Clearance For Actera Hip System
Conformis (NASDAQ: CFMS) has received 510(k) clearance from the U.S. Food and Drug Administration for its Actera Hip System.
Actera utilizes an advanced tri-taper femur stem design that facilitates direct anterior approach total hip arthroplasties, and provides an additional stem option to orthopedic surgeons.
Conformis Actera Hip System Receives 510(k) Clearance From The U.S. FDA
Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement products, today announced that it has received 510(k) clearance from the U.S. Food and Drug